Bluebird Bio Aktie Logo
US09609G2093

Bluebird Bio Aktie

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +12,00(+173,97%). Der Median liegt bei +10,96(+150,23%).

Kaufen
  14
Halten
  17
Verkaufen
  4

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

    SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebir.» Mehr auf businesswire.com


  • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

    WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right (“CVR”) if bluebird's c.» Mehr auf businesswire.com


  • bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

    SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additi.» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Bluebird Bio Aktie einen Umsatz von +35,78 Mio und ein Nettoeinkommen von 26,87 Mio
(EUR)März 2025
YOY
Umsatz+35,78 Mio107,93%
Bruttoeinkommen+24,47 Mio462,25%
Nettoeinkommen26,87 Mio58,46%
EBITDA22,75 Mio50,39%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+42,68 Mio
Anzahl Aktien
9,79 Mio
52 Wochen-Hoch/Tief
+25,08 - +2,81
DividendenNein
Beta
0,37
KGV (PE Ratio)
0,24
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,84
KUV (PS Ratio)
+0,47

Unternehmensprofil

Name
Bluebird Bio Aktie
CEO
Andrew Obenshain
Mitarbeiter248
🍪

Parqet nutzt Cookies.Erfahre Mehr